Grail (NASDAQ:GRAL) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research assumed coverage on shares of Grail (NASDAQ:GRAL) in a research report sent to investors on Friday morning, MarketBeat reports. The brokerage issued a peer perform rating on the stock.

Separately, Guggenheim assumed coverage on shares of Grail in a research note on Thursday, October 17th. They issued a “neutral” rating on the stock.

Grail Stock Down 6.4 %

GRAL traded down $1.01 during trading on Friday, hitting $14.80. 832,534 shares of the stock were exchanged, compared to its average volume of 1,094,071. Grail has a 1-year low of $12.33 and a 1-year high of $23.36. The company’s fifty day simple moving average is $13.82.

Grail (NASDAQ:GRAL) last announced its earnings results on Tuesday, August 13th. The company reported ($5.30) earnings per share (EPS) for the quarter. The firm had revenue of $31.97 million for the quarter.

Insider Buying and Selling at Grail

In other news, major shareholder Chun R. Ding bought 35,000 shares of the stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average price of $12.71 per share, with a total value of $444,850.00. Following the completion of the acquisition, the insider now directly owns 3,558,655 shares in the company, valued at approximately $45,230,505.05. The trade was a 0.99 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 58,829 shares of company stock worth $757,298.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.